Standard BioTools Inc. Basic Shares Outstanding (Weighted Average)
Standard BioTools Inc. (LAB) reported Basic Shares Outstanding (Weighted Average) of 390.88 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- Standard BioTools Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 390.88M shares, a 2.73% increase year-over-year.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 388.20M shares, a 2.64% increase year-over-year.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 385.09M shares, a 2.77% increase year-over-year.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 382.63M shares, a 2.99% increase year-over-year.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 381.62M shares, a 8.03% increase from fiscal 2024.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 353.25M shares, a 346.24% increase from fiscal 2023.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 79.16M shares, a 1.09% increase from fiscal 2022.
- Standard BioTools Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 78.31M shares, a 3.32% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 390.88M shares 10-Q · filed 2026-08-05 | 389.55M shares 10-Q · filed 2026-08-05 | 388.06M shares derived: average of 3 quarters · filed 2026-08-05 | 386.70M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 388.20M shares 10-Q · filed 2026-05-06 | 386.64M shares derived: average of 2 quarters · filed 2026-05-06 | 385.31M shares derived: average of 3 quarters · filed 2026-05-06 | 384.10M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 385.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 383.86M shares derived: average of 2 quarters · filed 2026-03-16 | 382.74M shares derived: average of 3 quarters · filed 2026-08-05 | 381.62M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 382.63M shares 10-Q · filed 2025-11-04 | 381.56M shares derived: average of 2 quarters · filed 2026-08-05 | 380.47M shares 10-Q · filed 2025-11-04 | 379.01M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 380.50M shares 10-Q · filed 2026-08-05 | 379.37M shares 10-Q · filed 2026-08-05 | 377.81M shares derived: average of 3 quarters · filed 2026-08-05 | 376.24M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 378.23M shares 10-Q · filed 2026-05-06 | 376.46M shares derived: average of 2 quarters · filed 2026-05-06 | 374.82M shares derived: average of 3 quarters · filed 2026-05-06 | 374.20M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 374.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 373.12M shares derived: average of 2 quarters · filed 2026-03-16 | 372.86M shares derived: average of 3 quarters · filed 2026-03-16 | 353.25M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 371.54M shares 10-Q · filed 2025-11-04 | 371.93M shares derived: average of 2 quarters · filed 2025-11-04 | 346.09M shares 10-Q · filed 2025-11-04 | 279.43M shares derived: average of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | 372.33M shares 10-Q · filed 2025-08-15 | 333.23M shares 10-Q · filed 2025-08-15 | 248.73M shares derived: average of 3 quarters · filed 2026-03-16 | 206.34M shares derived: average of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | 294.13M shares 10-Q · filed 2025-05-06 | 186.93M shares derived: average of 2 quarters · filed 2026-03-16 | 151.01M shares derived: average of 3 quarters · filed 2026-03-16 | 132.92M shares derived: average of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | 79.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 79.45M shares derived: average of 2 quarters · filed 2026-03-16 | 79.19M shares derived: average of 3 quarters · filed 2026-03-16 | 79.16M shares 10-K · filed 2026-03-16 |
| 2023-09-30 | 79.15M shares 10-Q · filed 2024-11-06 | 78.91M shares derived: average of 2 quarters · filed 2024-11-06 | 78.97M shares 10-Q · filed 2024-11-06 | 79.09M shares derived: average of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | 78.67M shares 10-Q · filed 2024-08-06 | 78.87M shares 10-Q · filed 2024-08-06 | 79.07M shares derived: average of 3 quarters · filed 2025-03-11 | 79.02M shares derived: average of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | 79.08M shares 10-Q · filed 2024-05-09 | 79.26M shares derived: average of 2 quarters · filed 2025-03-11 | 79.14M shares derived: average of 3 quarters · filed 2025-03-11 | 78.81M shares derived: average of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | 79.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 79.17M shares derived: average of 2 quarters · filed 2025-03-11 | 78.72M shares derived: average of 3 quarters · filed 2025-03-11 | 78.31M shares 10-K · filed 2025-03-11 |
| 2022-09-30 | 78.90M shares 10-Q · filed 2023-11-07 | 78.36M shares derived: average of 2 quarters · filed 2023-11-07 | 77.92M shares 10-Q · filed 2023-11-07 | 77.60M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 77.82M shares 10-Q · filed 2023-08-08 | 77.43M shares 10-Q · filed 2023-08-08 | 77.17M shares derived: average of 3 quarters · filed 2023-08-08 | 76.95M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 77.03M shares 10-Q · filed 2023-05-09 | 76.85M shares derived: average of 2 quarters · filed 2023-05-09 | 76.66M shares derived: average of 3 quarters · filed 2023-05-09 | 76.36M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 76.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 76.48M shares derived: average of 2 quarters · filed 2023-03-14 | 76.14M shares derived: average of 3 quarters · filed 2023-03-14 | 75.79M shares 10-K · filed 2023-03-14 |
| 2021-09-30 | 76.30M shares 10-Q · filed 2022-11-09 | 75.88M shares derived: average of 2 quarters · filed 2022-11-09 | 75.49M shares 10-Q · filed 2022-11-09 | 75.19M shares derived: average of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 75.45M shares 10-Q · filed 2022-08-09 | 75.08M shares 10-Q · filed 2022-08-09 | 74.82M shares derived: average of 3 quarters · filed 2022-08-09 | 74.23M shares derived: average of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | 74.71M shares 10-Q · filed 2022-05-09 | 74.50M shares derived: average of 2 quarters · filed 2022-05-09 | 73.83M shares derived: average of 3 quarters · filed 2022-05-09 | 73.10M shares derived: average of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | 74.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 73.39M shares derived: average of 2 quarters · filed 2022-03-08 | 72.57M shares derived: average of 3 quarters · filed 2022-03-08 | 72.04M shares 10-K · filed 2022-03-08 |
| 2020-09-30 | 72.49M shares 10-Q · filed 2021-11-09 | 71.70M shares derived: average of 2 quarters · filed 2021-11-09 | 71.29M shares 10-Q · filed 2021-11-09 | |
| 2020-06-30 | 70.92M shares 10-Q · filed 2021-08-06 | 70.69M shares 10-Q · filed 2021-08-06 | ||
| 2019-12-31 | 66.78M shares 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |